Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 12/2013

01.12.2013 | Original Paper

Specific expression of k63-linked ubiquitination of calmodulin-like protein 5 in breast cancer of premenopausal patients

verfasst von: Manuel Debald, Frank Alexander Schildberg, Andrea Linke, Klaus Walgenbach, Walther Kuhn, Gunther Hartmann, Gisela Walgenbach-Brünagel

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 12/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Posttranslational modifications such as ubiquitination regulate many functions of proteins by affecting their interaction with other molecules, their activity, and their subcellular localization. In cancer biology, the ubiquitin network has gained major interest. K63-linked ubiquitination has emerged as a posttranslational modification with functional consequences, as it acts in several processes such as protein trafficking, DNA repair, and inflammation. Moreover, k63-linked ubiquitination is involved in the regulation of carcinogenesis. Based on previous findings, the aim of this study was to evaluate the ubiquitination of CALML5 in breast cancer patients.

Patients and methods

The breast cancer cell lines SkBr3, MCF7, HCC1937, and BT474 as well as 23 tumor samples of patients with primary breast cancer and the normal adjacent breast tissue were analyzed by one-dimensional immunoblot.

Results

Using specific antibodies against CALML5 and k63-linked ubiquitin, we demonstrate a k63-linked ubiquitination in the nuclear fraction of premenopausal breast cancer patients. K63-linked ubiquitination of CALML5 was found in breast cancer tissue, but not found in surrounding healthy tissue.

Conclusion

Our findings support the concept that ubiquitination of CALML5 in the nucleus is involved in the carcinogenesis of breast cancer in premenopausal women.
Literatur
Zurück zum Zitat Bedford L, Lowe J, Dick LR, Mayer RJ, Brownell JE (2011) Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets. Nat Rev Drug Discov 10:29–46CrossRefPubMed Bedford L, Lowe J, Dick LR, Mayer RJ, Brownell JE (2011) Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets. Nat Rev Drug Discov 10:29–46CrossRefPubMed
Zurück zum Zitat Bernassola F, Karin M, Ciechanover A, Melino G (2008) The HECT family of E3 ubiquitin ligases: multiple players in cancer development. Cancer Cell 14:10–21CrossRefPubMed Bernassola F, Karin M, Ciechanover A, Melino G (2008) The HECT family of E3 ubiquitin ligases: multiple players in cancer development. Cancer Cell 14:10–21CrossRefPubMed
Zurück zum Zitat Brekelmans CT, van Gorp JM, Peeters PH, Collette HJ (1996) Histopathology and growth rate of interval breast carcinoma. Characterization of different subgroups. Cancer 78:1220–1228CrossRefPubMed Brekelmans CT, van Gorp JM, Peeters PH, Collette HJ (1996) Histopathology and growth rate of interval breast carcinoma. Characterization of different subgroups. Cancer 78:1220–1228CrossRefPubMed
Zurück zum Zitat Chau V, Tobias JW, Bachmair A, Marriott D, Ecker DJ, Gonda DK, Varshavsky A (1989) A multiubiquitin chain is confined to specific lysine in a targeted short-lived protein. Science 243:1576–1583CrossRefPubMed Chau V, Tobias JW, Bachmair A, Marriott D, Ecker DJ, Gonda DK, Varshavsky A (1989) A multiubiquitin chain is confined to specific lysine in a targeted short-lived protein. Science 243:1576–1583CrossRefPubMed
Zurück zum Zitat Chen Q, Xie W, Kuhn DJ, Voorhees PM, Lopez-Girona A, Mendy D, Corral LG, Krenitsky VP, Xu W, Moutouh-de PL, Webb DR, Mercurio F, Nakayama KI, Nakayama K, Orlowski RZ (2008) Targeting the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy. Blood 111:4690–4699PubMedCentralCrossRefPubMed Chen Q, Xie W, Kuhn DJ, Voorhees PM, Lopez-Girona A, Mendy D, Corral LG, Krenitsky VP, Xu W, Moutouh-de PL, Webb DR, Mercurio F, Nakayama KI, Nakayama K, Orlowski RZ (2008) Targeting the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy. Blood 111:4690–4699PubMedCentralCrossRefPubMed
Zurück zum Zitat Ciehanover A, Hod Y, Hershko A (1978) A heat-stable polypeptide component of an ATP-dependent proteolytic system from reticulocytes. Biochem Biophys Res Commun 81:1100–1105CrossRefPubMed Ciehanover A, Hod Y, Hershko A (1978) A heat-stable polypeptide component of an ATP-dependent proteolytic system from reticulocytes. Biochem Biophys Res Commun 81:1100–1105CrossRefPubMed
Zurück zum Zitat Debald M, Franken S, Heukamp LC, Linke A, Wolfgarten M, Walgenbach KJ, Braun M, Rudlowski C, Gieselmann V, Kuhn W, Hartmann G, Walgenbach-Brunagel G (2011) Identification of specific nuclear structural protein alterations in human breast cancer. J Cell Biochem 112:3176–3184CrossRefPubMed Debald M, Franken S, Heukamp LC, Linke A, Wolfgarten M, Walgenbach KJ, Braun M, Rudlowski C, Gieselmann V, Kuhn W, Hartmann G, Walgenbach-Brunagel G (2011) Identification of specific nuclear structural protein alterations in human breast cancer. J Cell Biochem 112:3176–3184CrossRefPubMed
Zurück zum Zitat Deshaies RJ, Joazeiro CA (2009) RING domain E3 ubiquitin ligases. Annu Rev Biochem 78:399–434CrossRefPubMed Deshaies RJ, Joazeiro CA (2009) RING domain E3 ubiquitin ligases. Annu Rev Biochem 78:399–434CrossRefPubMed
Zurück zum Zitat Di J, Zhang Y, Zheng J (2011) Reactivation of p53 by inhibiting Mdm2 E3 ligase: a novel antitumor approach. Curr Cancer Drug Targets 11:987–994CrossRefPubMed Di J, Zhang Y, Zheng J (2011) Reactivation of p53 by inhibiting Mdm2 E3 ligase: a novel antitumor approach. Curr Cancer Drug Targets 11:987–994CrossRefPubMed
Zurück zum Zitat Fredholm H, Eaker S, Frisell J, Holmberg L, Fredriksson I, Lindman H (2009) Breast cancer in young women: poor survival despite intensive treatment. PLoS ONE 4:e7695PubMedCentralCrossRefPubMed Fredholm H, Eaker S, Frisell J, Holmberg L, Fredriksson I, Lindman H (2009) Breast cancer in young women: poor survival despite intensive treatment. PLoS ONE 4:e7695PubMedCentralCrossRefPubMed
Zurück zum Zitat Fulda S, Vucic D (2012) Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Discov 11:109–124CrossRefPubMed Fulda S, Vucic D (2012) Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Discov 11:109–124CrossRefPubMed
Zurück zum Zitat Fulda S, Rajalingam K, Dikic I (2012) Ubiquitylation in immune disorders and cancer: from molecular mechanisms to therapeutic implications. EMBO Mol Med 4:545–556PubMedCentralCrossRefPubMed Fulda S, Rajalingam K, Dikic I (2012) Ubiquitylation in immune disorders and cancer: from molecular mechanisms to therapeutic implications. EMBO Mol Med 4:545–556PubMedCentralCrossRefPubMed
Zurück zum Zitat Getzenberg RH, Pienta KJ, Huang EY, Coffey DS (1991) Identification of nuclear matrix proteins in the cancer and normal rat prostate. Cancer Res 51:6514–6520PubMed Getzenberg RH, Pienta KJ, Huang EY, Coffey DS (1991) Identification of nuclear matrix proteins in the cancer and normal rat prostate. Cancer Res 51:6514–6520PubMed
Zurück zum Zitat Goldstein G, Scheid M, Hammerling U, Schlesinger DH, Niall HD, Boyse EA (1975) Isolation of a polypeptide that has lymphocyte-differentiating properties and is probably represented universally in living cells. Proc Natl Acad Sci USA 72:11–15PubMedCentralCrossRefPubMed Goldstein G, Scheid M, Hammerling U, Schlesinger DH, Niall HD, Boyse EA (1975) Isolation of a polypeptide that has lymphocyte-differentiating properties and is probably represented universally in living cells. Proc Natl Acad Sci USA 72:11–15PubMedCentralCrossRefPubMed
Zurück zum Zitat Hershko A, Ciechanover A, Heller H, Haas AL, Rose IA (1980) Proposed role of ATP in protein breakdown: conjugation of protein with multiple chains of the polypeptide of ATP-dependent proteolysis. Proc Natl Acad Sci USA 77:1783–1786PubMedCentralCrossRefPubMed Hershko A, Ciechanover A, Heller H, Haas AL, Rose IA (1980) Proposed role of ATP in protein breakdown: conjugation of protein with multiple chains of the polypeptide of ATP-dependent proteolysis. Proc Natl Acad Sci USA 77:1783–1786PubMedCentralCrossRefPubMed
Zurück zum Zitat Hoeller D, Hecker CM, Dikic I (2006) Ubiquitin and ubiquitin-like proteins in cancer pathogenesis. Nat Rev Cancer 6:776–788CrossRefPubMed Hoeller D, Hecker CM, Dikic I (2006) Ubiquitin and ubiquitin-like proteins in cancer pathogenesis. Nat Rev Cancer 6:776–788CrossRefPubMed
Zurück zum Zitat Huen MS, Grant R, Manke I, Minn K, Yu X, Yaffe MB, Chen J (2007) RNF8 transduces the DNA-damage signal via histone ubiquitylation and checkpoint protein assembly. Cell 131:901–914PubMedCentralCrossRefPubMed Huen MS, Grant R, Manke I, Minn K, Yu X, Yaffe MB, Chen J (2007) RNF8 transduces the DNA-damage signal via histone ubiquitylation and checkpoint protein assembly. Cell 131:901–914PubMedCentralCrossRefPubMed
Zurück zum Zitat Ikeda F, Crosetto N, Dikic I (2010) What determines the specificity and outcomes of ubiquitin signaling? Cell 143:677–681CrossRefPubMed Ikeda F, Crosetto N, Dikic I (2010) What determines the specificity and outcomes of ubiquitin signaling? Cell 143:677–681CrossRefPubMed
Zurück zum Zitat Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277–300CrossRefPubMed Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277–300CrossRefPubMed
Zurück zum Zitat Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90CrossRefPubMed Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90CrossRefPubMed
Zurück zum Zitat Kirkin V, Dikic I (2007) Role of ubiquitin- and Ubl-binding proteins in cell signaling. Curr Opin Cell Biol 19:199–205CrossRefPubMed Kirkin V, Dikic I (2007) Role of ubiquitin- and Ubl-binding proteins in cell signaling. Curr Opin Cell Biol 19:199–205CrossRefPubMed
Zurück zum Zitat Mailand N, Bekker-Jensen S, Faustrup H, Melander F, Bartek J, Lukas C, Lukas J (2007) RNF8 ubiquitylates histones at DNA double-strand breaks and promotes assembly of repair proteins. Cell 131:887–900CrossRefPubMed Mailand N, Bekker-Jensen S, Faustrup H, Melander F, Bartek J, Lukas C, Lukas J (2007) RNF8 ubiquitylates histones at DNA double-strand breaks and promotes assembly of repair proteins. Cell 131:887–900CrossRefPubMed
Zurück zum Zitat Mehul B, Bernard D, Simonetti L, Bernard MA, Schmidt R (2000) Identification and cloning of a new calmodulin-like protein from human epidermis. J Biol Chem 275:12841–12847CrossRefPubMed Mehul B, Bernard D, Simonetti L, Bernard MA, Schmidt R (2000) Identification and cloning of a new calmodulin-like protein from human epidermis. J Biol Chem 275:12841–12847CrossRefPubMed
Zurück zum Zitat Mehul B, Bernard D, Schmidt R (2001) Calmodulin-like skin protein: a new marker of keratinocyte differentiation. J Invest Dermatol 116:905–909CrossRefPubMed Mehul B, Bernard D, Schmidt R (2001) Calmodulin-like skin protein: a new marker of keratinocyte differentiation. J Invest Dermatol 116:905–909CrossRefPubMed
Zurück zum Zitat Newton K, Matsumoto ML, Wertz IE, Kirkpatrick DS, Lill JR, Tan J, Dugger D, Gordon N, Sidhu SS, Fellouse FA, Komuves L, French DM, Ferrando RE, Lam C, Compaan D, Yu C, Bosanac I, Hymowitz SG, Kelley RF, Dixit VM (2008) Ubiquitin chain editing revealed by polyubiquitin linkage-specific antibodies. Cell 134:668–678CrossRefPubMed Newton K, Matsumoto ML, Wertz IE, Kirkpatrick DS, Lill JR, Tan J, Dugger D, Gordon N, Sidhu SS, Fellouse FA, Komuves L, French DM, Ferrando RE, Lam C, Compaan D, Yu C, Bosanac I, Hymowitz SG, Kelley RF, Dixit VM (2008) Ubiquitin chain editing revealed by polyubiquitin linkage-specific antibodies. Cell 134:668–678CrossRefPubMed
Zurück zum Zitat Newton K, Matsumoto ML, Ferrando RE, Wickliffe KE, Rape M, Kelley RF, Dixit VM (2012) Using linkage-specific monoclonal antibodies to analyze cellular ubiquitylation. Methods Mol Biol 832:185–196CrossRefPubMed Newton K, Matsumoto ML, Ferrando RE, Wickliffe KE, Rape M, Kelley RF, Dixit VM (2012) Using linkage-specific monoclonal antibodies to analyze cellular ubiquitylation. Methods Mol Biol 832:185–196CrossRefPubMed
Zurück zum Zitat Porter D, Lahti-Domenici J, Keshaviah A, Bae YK, Argani P, Marks J, Richardson A, Cooper A, Strausberg R, Riggins GJ, Schnitt S, Gabrielson E, Gelman R, Polyak K (2003) Molecular markers in ductal carcinoma in situ of the breast. Mol Cancer Res 1:362–375PubMed Porter D, Lahti-Domenici J, Keshaviah A, Bae YK, Argani P, Marks J, Richardson A, Cooper A, Strausberg R, Riggins GJ, Schnitt S, Gabrielson E, Gelman R, Polyak K (2003) Molecular markers in ductal carcinoma in situ of the breast. Mol Cancer Res 1:362–375PubMed
Zurück zum Zitat Skaug B, Jiang X, Chen ZJ (2009) The role of ubiquitin in NF-kappaB regulatory pathways. Annu Rev Biochem 78:769–796CrossRefPubMed Skaug B, Jiang X, Chen ZJ (2009) The role of ubiquitin in NF-kappaB regulatory pathways. Annu Rev Biochem 78:769–796CrossRefPubMed
Zurück zum Zitat Steven AC, Bisher ME, Roop DR, Steinert PM (1990) Biosynthetic pathways of filaggrin and loricrin–two major proteins expressed by terminally differentiated epidermal keratinocytes. J Struct Biol 104:150–162CrossRefPubMed Steven AC, Bisher ME, Roop DR, Steinert PM (1990) Biosynthetic pathways of filaggrin and loricrin–two major proteins expressed by terminally differentiated epidermal keratinocytes. J Struct Biol 104:150–162CrossRefPubMed
Zurück zum Zitat Ulrich HD, Walden H (2010) Ubiquitin signalling in DNA replication and repair. Nat Rev Mol Cell Biol 11:479–489CrossRefPubMed Ulrich HD, Walden H (2010) Ubiquitin signalling in DNA replication and repair. Nat Rev Mol Cell Biol 11:479–489CrossRefPubMed
Zurück zum Zitat Unterkircher T, Cristofanon S, Vellanki SH, Nonnenmacher L, Karpel-Massler G, Wirtz CR, Debatin KM, Fulda S (2011) Bortezomib primes glioblastoma, including glioblastoma stem cells, for TRAIL by increasing tBid stability and mitochondrial apoptosis. Clin Cancer Res 17:4019–4030CrossRefPubMed Unterkircher T, Cristofanon S, Vellanki SH, Nonnenmacher L, Karpel-Massler G, Wirtz CR, Debatin KM, Fulda S (2011) Bortezomib primes glioblastoma, including glioblastoma stem cells, for TRAIL by increasing tBid stability and mitochondrial apoptosis. Clin Cancer Res 17:4019–4030CrossRefPubMed
Zurück zum Zitat Wang G, Gao Y, Li L, Jin G, Cai Z, Chao JI, Lin HK (2012) K63-linked ubiquitination in kinase activation and cancer. Front Oncol 2:5PubMedCentralPubMed Wang G, Gao Y, Li L, Jin G, Cai Z, Chao JI, Lin HK (2012) K63-linked ubiquitination in kinase activation and cancer. Front Oncol 2:5PubMedCentralPubMed
Zurück zum Zitat Xu P, Duong DM, Seyfried NT, Cheng D, Xie Y, Robert J, Rush J, Hochstrasser M, Finley D, Peng J (2009) Quantitative proteomics reveals the function of unconventional ubiquitin chains in proteasomal degradation. Cell 137:133–145PubMedCentralCrossRefPubMed Xu P, Duong DM, Seyfried NT, Cheng D, Xie Y, Robert J, Rush J, Hochstrasser M, Finley D, Peng J (2009) Quantitative proteomics reveals the function of unconventional ubiquitin chains in proteasomal degradation. Cell 137:133–145PubMedCentralCrossRefPubMed
Zurück zum Zitat Yang Y, Ludwig RL, Jensen JP, Pierre SA, Medaglia MV, Davydov IV, Safiran YJ, Oberoi P, Kenten JH, Phillips AC, Weissman AM, Vousden KH (2005) Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell 7:547–559CrossRefPubMed Yang Y, Ludwig RL, Jensen JP, Pierre SA, Medaglia MV, Davydov IV, Safiran YJ, Oberoi P, Kenten JH, Phillips AC, Weissman AM, Vousden KH (2005) Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell 7:547–559CrossRefPubMed
Zurück zum Zitat Zhang J, Wu P, Hu Y (2013) Clinical and marketed proteasome inhibitors for cancer treatment. Curr Med Chem 20:2537–2551CrossRefPubMed Zhang J, Wu P, Hu Y (2013) Clinical and marketed proteasome inhibitors for cancer treatment. Curr Med Chem 20:2537–2551CrossRefPubMed
Metadaten
Titel
Specific expression of k63-linked ubiquitination of calmodulin-like protein 5 in breast cancer of premenopausal patients
verfasst von
Manuel Debald
Frank Alexander Schildberg
Andrea Linke
Klaus Walgenbach
Walther Kuhn
Gunther Hartmann
Gisela Walgenbach-Brünagel
Publikationsdatum
01.12.2013
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 12/2013
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-013-1541-y

Weitere Artikel der Ausgabe 12/2013

Journal of Cancer Research and Clinical Oncology 12/2013 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.